Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2023-12-29 00:00:00 ET · period of report 2023-12-27 · accession 0001415889-23-017025 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-29 | 2023-12-27 | JBIO | Gillies Hunter | Chief MEDICAL Off | S - Sale+OE | $24.50 | -125 | 3,251 | -4% | -$3,062 |
| D | 2023-12-29 | 2023-12-27 | JBIO | Gillies Hunter | Chief MEDICAL Off | M - OptEx | $2.14 | +125 | 3,376 | +4% | +$267.50 |
| DM | 2023-12-29 | 2023-12-27 | JBIO | Gillies Hunter | Chief MEDICAL Off | M - OptEx | $0.00 | -125 | 16.3K | -0.8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-27 | S | D | 125 | $24.50 | 3,251 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-27 | M | A | 125 | $2.14 | 3,376 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-12-27 | M | D | 100 | $0.00 | 109,540 | D | $2.14 · — to 2031-04-01 | 100 Common Stock | (F3) A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments. |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-12-27 | M | D | 25 | $0.00 | 16,269 | D | $2.14 · — to 2031-04-01 | 25 Common Stock | (F2) A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. |